What is the 13F Pro Quality Score for NNVC?

13F Pro ranks NANOVIRICIDES, INC. (NNVC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NNVC's current score at https://13fpro.ai/research/NNVC (free sign-up required for the full ranking).

Where does 13F Pro source NNVC data?

All NANOVIRICIDES, INC. fundamentals and ownership data come directly from SEC EDGAR. NANOVIRICIDES, INC. files with the SEC under CIK 1379006. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NNVC in?

NANOVIRICIDES, INC. (NNVC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NNVC research updated on 13F Pro?

NNVC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

NANOVIRICIDES, INC.(NNVC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1379006 NNVC stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NNVC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for NANOVIRICIDES, INC. (NNVC), a Healthcare sector company. NNVC is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q3 2026), NANOVIRICIDES, INC. reports net income of $-2.0M, free cash flow of $-1.9M. Top institutional holders of NNVC by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, UBS Group AG, based on the most recent SEC filings. NNVC trades on the NYSE exchange and files with the SEC under CIK 1379006. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NNVC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NANOVIRICIDES, INC. directly from SEC EDGAR.

Revenue

Q3 2026

$0.00

Net Income

Q3 2026

$-2.0M

Free Cash Flow

Q3 2026

$-1.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$0.00FY 2025

FY22 —FY23 $0.00FY24 $0.00FY25 $0.00

Net Income

-14.1% YoY

$-9.5MFY 2025

FY22 $-8.1MFY23 $-8.6MFY24 $-8.3MFY25 $-9.5M

Operating Income

-12.6% YoY

$-9.6MFY 2025

FY22 $-8.1MFY23 $-8.9MFY24 $-8.5MFY25 $-9.6M

EPS (Diluted)

+10.0% YoY

$-0.63FY 2025

FY22 $-0.70FY23 $-0.74FY24 $-0.70FY25 $-0.63

Total Assets

-31.2% YoY

$8.8MFY 2025

FY22 $23.5MFY23 $16.9MFY24 $12.8MFY25 $8.8M

Op. Cash Flow

-34.3% YoY

$-8.5MFY 2025

FY22 $-5.9MFY23 $-5.7MFY24 $-6.3MFY25 $-8.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$0.00	$0.00	$0.00	—	—	—
Net Income	$-9.5M -14.1%	$-8.3M +3.4%	$-8.6M -5.9%	$-8.1M +39.7%	$-13.4M -59.6%	$-8.4M
Operating Income	$-9.6M -12.6%	$-8.5M +4.8%	$-8.9M -10.2%	$-8.1M -1.5%	$-8.0M +7.7%	$-8.7M
EPS (Diluted)	$-0.63 +10.0%	$-0.70 +5.4%	$-0.74 -5.7%	$-0.70	—	—
Total Assets	$8.8M -31.2%	$12.8M -24.1%	$16.9M -28.1%	$23.5M -1.8%	$23.9M +77.8%	$13.4M
Operating Cash Flow	$-8.5M -34.3%	$-6.3M -11.4%	$-5.7M +3.8%	$-5.9M +11.6%	$-6.7M +2.0%	$-6.8M

AI Insight: NNVC Financial Trends

NNVC remains pre-revenue with persistent $2M quarterly losses and equity eroding from $11M to $9M over eight quarters.

• Revenue has remained at $0M across all eight quarters from Q2 2024 through Q1 2026.

• Net income and operating income stable at −$2M per quarter since Q4 2024, but equity declined from $11M (Q2 2024) to $9M (Q1 2026).

⚠ Equity base has shrunk ~18% over the period; at current burn rate of ~$8M annually, runway appears limited without capital raise or revenue inflection.

⚠ Q4 2025 equity spike to $11M suggests potential financing event; sustainability unclear given return to $9M in Q1 2026.

AI Insight: NNVC Ratio Trends

Nanoviricides remains persistently unprofitable with negative ROE, ROA, and ROIC across all periods, with no sign of recovery toward breakeven.

• ROE deteriorated from -82.2% in Q2 2024 to -88.7% (annualized) in Q1 2026, widening shareholder value destruction.

• ROA worsened from -73.5% in Q2 2024 to -77.9% in Q1 2026, indicating asset base is not generating positive returns.

⚠ Q3 2025 marked peak negative ROE at -111.5%; recovery since then to -86.9% suggests volatility rather than structural improvement.

⚠ All profitability and efficiency metrics remain unavailable (OpMargin, NPM, D/E), limiting visibility into operational trajectory.

Get alerted when NNVC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NANOVIRICIDES, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NNVC

VANGUARD CAPITAL MANAGEMENT LLC
$466.5K511,477 sh
GEODE CAPITAL MANAGEMENT, LLC
$205.6K225,381 sh
UBS Group AG
$194.6K213,359 sh
BlackRock, Inc.
$144.8K158,752 sh
RENAISSANCE TECHNOLOGIES LLC
$123.0K134,900 sh
Miller Financial Services LLC
$95.8K105,000 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$90.3K99,031 sh
VANGUARD FIDUCIARY TRUST CO
$82.1K90,060 sh
Squarepoint Ops LLC
$53.0K58,138 sh
STATE STREET CORP
$49.4K54,206 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$466.5K	511,477
GEODE CAPITAL MANAGEMENT, LLC	$205.6K	225,381
UBS Group AG	$194.6K	213,359
BlackRock, Inc.	$144.8K	158,752
RENAISSANCE TECHNOLOGIES LLC	$123.0K	134,900
Miller Financial Services LLC	$95.8K	105,000
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$90.3K	99,031
VANGUARD FIDUCIARY TRUST CO	$82.1K	90,060
Squarepoint Ops LLC	$53.0K	58,138
STATE STREET CORP	$49.4K	54,206

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NNVC on your watchlist

Track score changes the day NANOVIRICIDES, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NNVC a good stock to buy?

13F Pro's AI-powered analysis of NANOVIRICIDES, INC. (NNVC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NNVC are available on the NNVC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NNVC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NNVC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NANOVIRICIDES, INC.'s investment landscape.